Skip to content

Study · Animal study (in vivo) · mouse · 2017

8 results

The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice.

Thomsen M, Dencker D, Wörtwein G, Weikop P, Egecioglu E, Jerlhag E, Fink-Jensen A, Molander A

Pharmacology, biochemistry, and behavior1 Aug 2017Cited by 88 (Europe PMC)

PMID28778739 (opens in a new tab)DOI10.1016/j.pbb.2017.07.014 (opens in a new tab)PepBankPUB-28778739
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Exendin‑4 prevented the deprivation-induced rise in alcohol intake versus saline throughout treatment.

    In plain wordsIn mice, Exendin‑4 prevented increased alcohol intake after deprivation compared with saline throughout treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseRelapse-like alcohol intake
    Study

    mousen: not reported in source

    Socially housed male C57BL/6NTac mice
    Comparator
    Saline
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    1.5 μg/kg/day · subcutaneous · 8 days during alcohol deprivation and 8 additional days after alcohol reintroductionAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 prevented the deprivation-induced increase in alcohol intake observed in control mice, without significantly affecting total fluid intake, body weight, or locomotor activity.
    4 context sentences
    Summary · context
    The effect was maintained undiminished throughout the treatment period.
    Summary · context
    Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37days.
    Summary · context
    Then, alcohol bottles were removed and Exendin-4 (1.5μg/kg/day) or saline was administered subcutaneously for 8days during alcohol deprivation.
    Summary · context
    Treatment continued for 8 additional days after reintroducing access to alcohol.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Exendin‑4 did not significantly change total fluid intake versus saline.

    In plain wordsIn mice, Exendin‑4 did not significantly change total fluid intake compared with saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTotal fluid intake
    Study

    mousen: not reported in source

    Socially housed male C57BL/6NTac mice
    Comparator
    Saline
    Outcome group
    Appetite and food intake · Mental health and mood
    Studied dose
    1.5 μg/kg/day · subcutaneous · 8 days during alcohol deprivation and 8 additional days after alcohol reintroductionAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 prevented the deprivation-induced increase in alcohol intake observed in control mice, without significantly affecting total fluid intake, body weight, or locomotor activity.
    3 context sentences
    Summary · context
    Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37days.
    Summary · context
    Then, alcohol bottles were removed and Exendin-4 (1.5μg/kg/day) or saline was administered subcutaneously for 8days during alcohol deprivation.
    Summary · context
    Treatment continued for 8 additional days after reintroducing access to alcohol.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Exendin‑4 did not significantly change body weight versus saline.

    In plain wordsIn mice, Exendin‑4 did not significantly change body weight compared with saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBody weight
    Study

    mousen: not reported in source

    Socially housed male C57BL/6NTac mice
    Comparator
    Saline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 μg/kg/day · subcutaneous · 8 days during alcohol deprivation and 8 additional days after alcohol reintroductionAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 prevented the deprivation-induced increase in alcohol intake observed in control mice, without significantly affecting total fluid intake, body weight, or locomotor activity.
    3 context sentences
    Summary · context
    Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37days.
    Summary · context
    Then, alcohol bottles were removed and Exendin-4 (1.5μg/kg/day) or saline was administered subcutaneously for 8days during alcohol deprivation.
    Summary · context
    Treatment continued for 8 additional days after reintroducing access to alcohol.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Exendin‑4 did not significantly change locomotor activity versus saline.

    In plain wordsIn mice, Exendin‑4 did not significantly change movement compared with saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeLocomotor activity
    Study

    mousen: not reported in source

    Socially housed male C57BL/6NTac mice
    Comparator
    Saline
    Outcome group
    Exercise and physical function · Mental health and mood
    Studied dose
    1.5 μg/kg/day · subcutaneous · 8 days during alcohol deprivation and 8 additional days after alcohol reintroductionAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 prevented the deprivation-induced increase in alcohol intake observed in control mice, without significantly affecting total fluid intake, body weight, or locomotor activity.
    3 context sentences
    Summary · context
    Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37days.
    Summary · context
    Then, alcohol bottles were removed and Exendin-4 (1.5μg/kg/day) or saline was administered subcutaneously for 8days during alcohol deprivation.
    Summary · context
    Treatment continued for 8 additional days after reintroducing access to alcohol.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Exendin‑4 prolonged latency to the first alcohol drink versus saline.

    In plain wordsIn mice, Exendin‑4 delayed the first alcohol drink compared with saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseLatency to first alcohol drink
    Study

    mousen: not reported in source

    Socially housed male C57BL/6NTac mice
    Comparator
    Saline
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    1.5 μg/kg/day · subcutaneous · 8 days during alcohol deprivation and 8 additional days after alcohol reintroductionAs given in this study (mouse).

    Source sentences

    Summary
    The reduced alcohol intake was caused by a protracted latency to the first drink of alcohol and a reduced number of drinking bouts, while bout size and duration were not affected.
    3 context sentences
    Summary · context
    Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37days.
    Summary · context
    Then, alcohol bottles were removed and Exendin-4 (1.5μg/kg/day) or saline was administered subcutaneously for 8days during alcohol deprivation.
    Summary · context
    Treatment continued for 8 additional days after reintroducing access to alcohol.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Exendin‑4 reduced the number of drinking bouts versus saline.

    In plain wordsIn mice, Exendin‑4 reduced the number of drinking bouts compared with saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseDrinking bout count
    Study

    mousen: not reported in source

    Socially housed male C57BL/6NTac mice
    Comparator
    Saline
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    1.5 μg/kg/day · subcutaneous · 8 days during alcohol deprivation and 8 additional days after alcohol reintroductionAs given in this study (mouse).

    Source sentences

    Summary
    The reduced alcohol intake was caused by a protracted latency to the first drink of alcohol and a reduced number of drinking bouts, while bout size and duration were not affected.
    3 context sentences
    Summary · context
    Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37days.
    Summary · context
    Then, alcohol bottles were removed and Exendin-4 (1.5μg/kg/day) or saline was administered subcutaneously for 8days during alcohol deprivation.
    Summary · context
    Treatment continued for 8 additional days after reintroducing access to alcohol.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Exendin‑4 did not affect drinking bout size versus saline.

    In plain wordsIn mice, Exendin‑4 did not affect drinking bout size compared with saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDrinking bout size
    Study

    mousen: not reported in source

    Socially housed male C57BL/6NTac mice
    Comparator
    Saline
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    1.5 μg/kg/day · subcutaneous · 8 days during alcohol deprivation and 8 additional days after alcohol reintroductionAs given in this study (mouse).

    Source sentences

    Summary
    The reduced alcohol intake was caused by a protracted latency to the first drink of alcohol and a reduced number of drinking bouts, while bout size and duration were not affected.
    3 context sentences
    Summary · context
    Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37days.
    Summary · context
    Then, alcohol bottles were removed and Exendin-4 (1.5μg/kg/day) or saline was administered subcutaneously for 8days during alcohol deprivation.
    Summary · context
    Treatment continued for 8 additional days after reintroducing access to alcohol.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Exendin‑4 did not affect drinking bout duration versus saline.

    In plain wordsIn mice, Exendin‑4 did not affect drinking bout duration compared with saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDrinking bout duration
    Study

    mousen: not reported in source

    Socially housed male C57BL/6NTac mice
    Comparator
    Saline
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    1.5 μg/kg/day · subcutaneous · 8 days during alcohol deprivation and 8 additional days after alcohol reintroductionAs given in this study (mouse).

    Source sentences

    Summary
    The reduced alcohol intake was caused by a protracted latency to the first drink of alcohol and a reduced number of drinking bouts, while bout size and duration were not affected.
    3 context sentences
    Summary · context
    Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37days.
    Summary · context
    Then, alcohol bottles were removed and Exendin-4 (1.5μg/kg/day) or saline was administered subcutaneously for 8days during alcohol deprivation.
    Summary · context
    Treatment continued for 8 additional days after reintroducing access to alcohol.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.